Jun 10, 2021 | News Release
Pomona – 06/10/2021 – PSC Biotech® and PSC Software™ today announced the immediate availability of the Beta version of ACE SuperVision, a module that integrates wearable technology devices with PSC’s™ Adaptative Compliance Engine® (ACE™). ACE SuperVision Beta allows users to browse ACE™ records, follow predefined workflows, record, view, verify, and submit data to their ACE™ instance will be available first using the Google Glass Enterprise Edition 2 wearable technology. This new version enables live video calls implementing Zoom, and features secure login, time out functionality and other features account security and data integrity features.
Future releases of ACE SuperVision will add capabilities for additional wearable and portable technology devices.
ACE SuperVision takes our ACE™ electronic quality management system (eQMS) to the next level, adding the flexibility of wearable technology, to provide capability to integrate on-line data acquisition, remote inspection and validation, and execution and monitoring operations. ACE SuperVision adds to the industry leading ACE™ eQMS value proposition.
CSO, PSC Biotech®
The development of the new module is a product of PSC Software’s™ customer feedback driven commitment to develop and deliver the electronic Quality Management System that meets all of our customers need.
Contact your PSC Software™ representative or PSC Software for availability of ACE SuperVision Beta.
Jan 18, 2021 | News Release
We’re growing! At PSC Biotech Corporation, we take great pleasure in announcing that, in light of our remarkable continuous growth over the last several years, we are expanding our operations: In conjunction with our business divisions in the US, EU, China and India, we are happy to announce the creation of our new Latin America business division to better serve the needs of our existing and future customers in the region. We will now be providing our premier professional services—including our impressive portfolio of innovative products and services and novel quality software solutions—to the pharmaceutical and medical devices manufacturing industry in Latin America. For more information about our company and products, please visit our webpage www.biotech.com. We look forward to continuing our business growth and better supporting our present and future customers and business partners.
PSC Biotech Corporation Latin America Division
Jorge Sugranes – Latin America Regional Director, Dallas TX jsugranes@biotech.com
Sep 1, 2020 | Computerized Systems
What is an Adverse Event Reporting System (AERS)?
The Adverse Event Reporting System (AERS) is a computerized information database designed to support the life sciences, healthcare, biotechnology & FDA agency post-marketing safety surveillance program for all approved drug and therapeutic biologic products. Regulatory authorities and agencies use AERS to monitor new adverse events and medication errors that might occur with these marketed products. Reporting of adverse events from the point of care is voluntary. FDA receives some adverse event and medication error reports directly from health care professionals such as physicians, pharmacists, nurses, and consumers (such as patients, family members, lawyers and others).
Organizations operating in the healthcare domain must have processes and procedures in place to meet the AERS regulations set by authorities
Why is an AERS important?
Adverse Events Reporting System is crucial for detecting, processing & reporting adverse drug & supplement-associated events. Thus, reporting via an AERS is fundamental to detecting subject safety issues and mitigate the relevant risks with planning. This is the reason healthcare and life sciences companies are required to clearly state the method by which the adverse events will be monitored & reported. This also includes stating the provisions to ensure safety, care and medical support for those experiencing unfavourable signs & symptoms during a clinical trial.
How does AERS work?
Safety Database
A safety database is used to manage safety reports incoming from multiple research & study centres where the clinical trials are conducted. This database or repository of all the adverse cases can be analyzed together to flag potential trends amongst the cases. The review and analysis of the safety of a given healthcare product is given by the safety committee, which is composed of a group of experts in the field.
Recording Adverse Events
To efficiently evaluate safety information pertaining to a clinical trial, the safety reports of an organization must satisfy the reporting threshold set by regulatory agencies like the FDA. In the case of a large volume of independent adverse event reports that lack context and clarity, evaluating the safety information becomes impossible.
Thus, to maintain the integrity of the safety process and protect human counterparts, the following things must be considered while recording an adverse clinical trial event;
- Severity or intensity (mild, moderate or severe)
- Study intervention relationship
- Action taking as per the study intervention
- Outcome of the adverse event
- Whether the adverse event is serious or non-serious
The above AERS compliance requirements determine the reporting procedures that must be followed.
Need adverse event reporting system planning?
PSC Biotech will assist you in creating a strategic roadmap for determining what data should be collected and what processes need to be in place to ensure compliance with regulations, including definitions and approaches to define the roles, responsibilities, processes, forms, the communication of adverse events and the follow-up activities to ensure that complete information is obtained.
Get in touch with PSC Biotech today!
Aug 25, 2020 | Consultant Tells All
What is Gap Analysis?
Gap Analyses is the systematic, documented review of an organization’s current state to identify gaps or opportunities for continuous improvement in “whatever”, be it quality systems, corporate governance, process optimization, operational efficiency, internal audit, or financial reporting. Biotechnology, Life Sciences and Healthcare organizations conduct gap analyses as a part of their continuous improvement programs.
What do Gap Analyses tell us?
Gap analyses tells you what you are doing now, how it compares to the current state-of-the-art, and what you need to do to bring your practices up to the current Good Practice used in your industry. You and your team work to close these ‘gaps’ and improve your systems and efficiency.
How is Gap Analysis conducted?
Audit companies conduct gap analyses in five phases;
Phase 1 – Planning and Preparation
This is the phase where the scope of analysis, problems, goals, and tasks are planned out. A gap analysis questionnaire is formulated along with the content, format, and schedule to conduct the gap analysis.
Phase 2 – Reviewing Background Information
In this phase, we review documents, reports, and evidence.
Phase 3 – Interviews with Stakeholders
Managers, process owners, service managers, and management personnel are interviewed in this phase. The interviews are based on the questionnaire prepared in Phase-1 of the analysis planning. This is crucial to identify and establish problems, inefficiencies and a common consensus about the goals that need to be achieved post the gap analysis, and possible solutions.
Phase 4 – Review of Draft Gap Analysis
In this phase, the stakeholders, teams and other personnel can review the result of the analyses from previous phases. It is the final step whereby the stakeholders can ensure that all the gaps have been included and nothing is missing in the draft Gap Analysis.
Phase 5 – Delivery of Final Formal Report
The final formal report contains the findings within the processes, systems and patterns of operation of the organization. Here, the stakeholders can add notes in the formal report to include the recommendations for short, medium, and long-term goals to make your gaps “disappear”.
Need a gap analyses audit expert? Contact PSC Biotech for cutting-edge quality engineer gap analysis expertise.
Aug 18, 2020 | Computerized Systems
Accurate record management is a crucial operation for the organizations in Biotechnology, Life sciences, Pharmaceutical and Medical Equipment domains. The document content is growing enormously and manual sorting of the records makes it tedious & prone to errors. This is where Electronic Document Management Systems comes into the picture. Organizations in the life science industry utilize cloud-based document management software to create, modify, and maintain documents to ensure accuracy, fast retrieval and audit.
What are the challenges posed by manual document management?
Manual document management has become obsolete in the life sciences industry due to multiple challenges and inefficiencies. Some of them are;
Tedious Team Collaboration
Manual preparation of the documents is a time-intensive process that requires collaborative work. If the workflow is not streamlined, errors and delays often occur. This makes the records less reliable than automated records.
Inherent Risks of Manual Document Management
The manual process of document management leaves it prone to many human errors. This might include losing a critical document, wrong filing, erroneous labelling and misinterpretation of information. This also points to poor revision and update procedures as there are no reminders for the human users to do so.
Tracking Changes is Difficult
Keeping a track of all the versions and the relevant changes in them is a big challenge for life science companies that are using manual document management systems. This sometimes poses regulatory challenges due to the unavailability of the latest version of the document. A document might be required beforehand before its revision date has arrived and that becomes a challenge!
Logistical Challenges
Physical documents require dedicated and secure storage space which maintain optimum environmental parameters. Crucial records are often stored in fire-proof and waterproof cabinets that require more space. Moreover, access to the storage has to be monitored for security & integrity of the data.
How does an Electronic Document System mitigate the above challenges?
A cloud-based Electronic Records Management system is fast, reliable, secure and efficient. Following are its benefits in the life sciences industry.
Cloud Storage and Automation
An Electronic Document Management system eliminates the need for physical document processes. Automated uploads, scanning & recognition save tonnes of labour and mistakes in maintaining crucial data about the patients.
Seamless Information Retrieval
Most advanced EDM systems come with advanced search and record retrieval features. From simple string search for the document title to page controls and tags, EDMs allow access to the latest version of any given document at any time.
Version Tracking & Security
Electronic Document Management Systems keep a track of all the versions of a document with time stamps. Moreover, watermarks can be placed on the documents as per their usage. For. e.g. Confidential, For Training, Controlled Copy, Uncontrolled Copy, etc. This also makes the process of updating documents much easier.
Regulatory Compliance
State-of-art Electronic Document Management systems come enabled with all the regulatory mandates. For instance, PSC Biotech’s EDM software is compliant with EU Annex 11, ISO, MHRA & WHO. The teams can access features like audit trails, e-signatures and 2-level authentication for every document.
Need a Reliable EDM Software for Your Life Science Company?
For over ten years PSC Software™ has provided cloud-based document management software for life science companies around the globe. If you would like to know how we can help your company optimize record management and streamline your business, get in touch with us today!
